Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Racism is a public health issue

Racism is still pernicious, pervasive and cutting short the lives of black Americans to this day.

State of patient centricity 2020: Advancing from patient-first intentions to true co-creation

Patient centricity is a near-universal goal in pharmaceutical research and development, but one without a commonly accepted definition. The challenge now is putting it into practice and understanding its impact on clinical trials. This Economist Intelligence Unit study, sponsored by Medidata, draws on insights from patient advocates, leading pharmaceutical and clinical research industry executives and extensive desk research.

The workplace response to neurological conditions: A focus on migraine, multiple sclerosis and Alzheimer’s disease

Migraine, multiple sclerosis (MS) and Alzheimer’s disease (AD) affect over 1.3bn people globally. The report  looks at the impact of these three neurological conditions on both patients and carers in the workplace.

Value-based healthcare in Sweden: Reaching the next level

The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.

Women’s health and well-being


How do definitions of women’s well-being vary by region, age and income? Our new infographic, sponsored by Merck Consumer Health explores.

Infographic | Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

Country Infographics

Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

Lung cancer is the most fatal cancer worldwide. By 2050 the global burden of lung cancer is projected to increase to 3.8m new cases and 3.2m deaths per year, with the greatest burden expected in East Asia, at 1.7m new cases and 1.5m deaths.1

The Economist Impact report, "Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan," sponsored by MSD, evaluates the various policies impacting lung cancer care in the three countries under the following five domains:

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

By December 2020, several potential covid-19 vaccines were showing promise in clinical trials. And by the middle of 2021, a vaccine was available to the public. Very few people had been optimistic that such a feat could be achieved. In many ways, it was a perfect storm. The fast development of covid-19 vaccines benefited from years of previous research on related viruses and vaccine trials that used mRNA. It’s said the research matured at just the right time, and that mRNA technology would not have been ready even five years ago.

The longevity equation: climate resilience for health in the Middle East

Climate change is one of the most complex threats to the health of our people and our planet. The Middle East is among the geographic areas most vulnerable to rising temperatures, air pollution, food and water insecurity and adverse weather events. Without considerable mitigation and adaptation efforts, the health and longevity of current and future generations will be severely impacted.

 

Musculoskeletal Injuries in Australia: Current Challenges and Opportunities

Musculoskeletal disorders (MSDs), affecting an estimated 1.71 billion people globally, are a leading cause of disability and rehabilitation needs, accounting for 149 million years lived with disability.1

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week